Should I wait for retatrutide instead of starting semaglutide?

No approval date for retatrutide is confirmed, so waiting means going without an approved treatment for an unknown period. Whether to start an available option now or wait is a decision to make with a clinician, not around a rumored launch.

Is retatrutide safer than semaglutide?

This is not known. Retatrutide is still in trials, so its long-term safety profile is not established. Semaglutide has years of post-marketing safety data by comparison.

How much more weight might retatrutide produce?

In separate trials, retatrutide reached roughly 24% at 48 weeks versus about 14.9% for semaglutide in STEP 1. Because these are different trials at different phases, the gap is not a confirmed head-to-head difference.

Head-to-head comparisons

Retatrutide vs Semaglutide for Women: How They Compare

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP · Updated July 2026

Quick answer

Semaglutide (Wegovy) is an FDA-approved GLP-1 drug that produced about 14.9% mean weight loss in the STEP 1 trial. Retatrutide is an investigational triple agonist that reached roughly 24% in a phase 2 trial but is not FDA-approved or available. For women choosing today, semaglutide is an established option and retatrutide is not.

An established GLP-1 vs an investigational triple agonist

Semaglutide is a single-target GLP-1 receptor agonist, FDA-approved for chronic weight management as Wegovy and for type 2 diabetes as Ozempic and Rybelsus. It has years of post-marketing use and a large body of trial data.

Retatrutide activates three receptors, GIP, GLP-1, and glucagon. It is being studied for weight management but has not completed the phase 3 program the FDA requires, so it is not approved and not commercially available.

Efficiency ceiling and the timeline to market

In STEP 1, semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks. Retatrutide reached roughly 24% at 48 weeks in phase 2. The higher early figure is a reason retatrutide is watched closely, but a phase 2 result is not a confirmed efficacy ceiling.

For anyone weighing whether to wait, the honest answer is that no approval date is confirmed. Waiting for an investigational drug means going without an approved treatment in the meantime, which is a decision to make with a clinician rather than around a rumored launch.

What women should weigh

Semaglutide has a defined label for pregnancy and breastfeeding: stop at least 2 months before a planned pregnancy because of its long half-life, and avoid use while breastfeeding. It does not carry the oral-contraceptive warning that tirzepatide does.

Retatrutide has no approved label, so there is no comparable published guidance for women. Access is limited to clinical trials, which set their own contraception requirements for participants.

Key points

Semaglutide (Wegovy) is FDA-approved for weight; retatrutide is investigational and unavailable.
STEP 1 showed ~14.9% for semaglutide; retatrutide reached ~24% in phase 2 only.
No confirmed retatrutide approval date exists; waiting means going without an approved option.
Semaglutide has a full pregnancy and breastfeeding label; retatrutide has none.

Molecule facts (canonical explainers)

This is a decision guide. For the plain-fact explainer of each molecule (mechanism, FDA status, dosing cautions), see:

Retatrutide for women — GIP/GLP-1/glucagon receptor triple agonist (investigational)
Wegovy for women — GLP-1 receptor agonist (semaglutide 2.4 mg)

Providers we review in this area

Editorial reviews only — not treatment recommendations. Prescribing decisions rest with a licensed clinician. For the full directory, see all GLP-1 for women providers.

Form Health — Board-certified obesity medicine physicians prescribing GLP-1s. Often insurance-covered — among the most affordable options when insurance applies.
Noom Med — Noom’s GLP-1 telehealth arm pairing semaglutide/tirzepatide prescribing with behavior-change coaching.
Plushcare GLP-1 — Primary care telehealth that prescribes Wegovy and Zepbound when clinically appropriate. Insurance-friendly.

Cost

Semaglutide (Wegovy) self-pay is about $499 per month via NovoCare, with a list price near $1,349. Retatrutide has no commercial price because it is not available.

See the full cost breakdown in our How much does Wegovy cost?.

Frequently asked questions

Should I wait for retatrutide instead of starting semaglutide?: No approval date for retatrutide is confirmed, so waiting means going without an approved treatment for an unknown period. Whether to start an available option now or wait is a decision to make with a clinician, not around a rumored launch.
Is retatrutide safer than semaglutide?: This is not known. Retatrutide is still in trials, so its long-term safety profile is not established. Semaglutide has years of post-marketing safety data by comparison.
How much more weight might retatrutide produce?: In separate trials, retatrutide reached roughly 24% at 48 weeks versus about 14.9% for semaglutide in STEP 1. Because these are different trials at different phases, the gap is not a confirmed head-to-head difference.

Sources

Every efficacy, safety, and price claim above resolves to an FDA label, published trial, guideline, or manufacturer / GoodRx pricing page. External links open in a new tab.

Keep reading

ClearHormones updates these guides as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.